Clinical trial on COVID-19 patients
The Materialise NIP Connector and the designs are available. We have tested it on healthy people and we are fast tracking the regulatory registration in Europe and in the US. At the same time, we are upscaling production to be able to deliver this broadly to the clinical community.
In parallel, we are supporting a clinical trial to determine what the effect of the Passive NIP is on COVID-19 patients. Our clinical partners are hoping to provide some clinical guidance regarding the optimal use of the Materialise Passive NIP.
As Prof. De Backer notes, “Except for the new 3D-printed connector, the components of the mask exist and the concept is already known. We’ve used it for years in non-invasive and invasive ventilation. In the trial we will identify what the effect is on COVID-19 patients and at what stage of the disease to best use this NIP solution. We think that it is important to start very early, so just when the infection or the inflammation in the lower airways starts, and that at that time we switch from pure oxygen to this combined treatment with oxygen and with pressure.”
At Materialise, we realize that many hospitals are in dire need so we will work with them to provide this as an emergency solution in compliance with local regulation. We are also open for partnering with others in order to accelerate access for patients around the world.
Collaboration is more important than ever as we face the global coronavirus pandemic and the associated shortage of ventilators and other medical equipment.